Home About ATSDR Press Room A-Z Index Glossary Employment Training Contact Us CDC  
ATSDR/DHHS Agency for Toxic Substances and Disease Registry Agency for Toxic Substances and Disease Registry Department of Health and Human Services ATSDR en Español

Search:

Toxic Substances and Health
 
Section Contents
 
Acute Exposure
Chronic Exposure
Challenge
 
Case Contents
 
Cover Page
Goals and Objectives
Case Study, Pretest
Who is at Risk
Exposure Pathways
Biological Fate
Physiologic Effects
Clinical Evaluation
Standards, Regulations
Suggested Reading List
Related Documents
Answers
Sources of Information
 
Printable version Printer-friendly
 
Case Studies (CSEM)
 
CSEM Home
Continuing Education
Online Registration
 
ATSDR Resources
 
Case Studies (CSEM)
Exposure Pathways
GATHER (GIS)
Health Assessments
Health Statements
Interaction Profiles
Interactive Learning
Managing Incidents
Medical Guidelines
Minimal Risk Levels
Priority List
ToxFAQs™
ToxFAQs™ CABS
Toxicological Profiles
Toxicology Curriculum
 
External Resources
 
CDC
eLCOSH
EPA
Healthfinder®
Medline Plus
NCEH
NIEHS
NIOSH
OSHA
 

Agency for Toxic Substances and Disease Registry
Stoddard Solvent Toxicity
Treatment and Management


Acute Exposure

  • There are no known antidotes for Stoddard solvent toxicity. Treatment consists of supportive measures and prevention of further overexposure.

In cases of acute inhalation exposure to Stoddard solvent, the person should be removed immediately from the source of exposure. After initial evaluation and treatment to maintain respiratory and cardiovascular functions, decontamination procedures should be instituted. Remove contaminated clothing and wash exposed areas with mild soap and shampoo, then rinse thoroughly with water. Direct eye splashes should be treated by irrigation with saline or water for 15 minutes or until pain resolves.

Inhalation exposure may cause respiratory, circulatory, or mental status changes. Supplemental oxygen should be administered as needed. Further evaluation, including blood gas analyses, chest radiography, ECG monitoring, and baseline liver and kidney function tests, should be considered in serious overexposures.

Because the threat of systemic toxicity is low after Stoddard solvent ingestion and because of potential for pulmonary aspiration, gastric decontamination (i.e., emesis, lavage, cathartic, activated charcoal) is not recommended in most cases. Corticosteroids and prophylactic antibiotics are not necessary to treat persons with Stoddard solvent ingestion and pulmonary aspiration. An initial chest radiograph should be obtained to determine baseline, and the patient should be observed for 6 hours. Patients who are asymptomatic after 6 hours of observation may be discharged from the hospital. Patients who develop chemical pneumonitis will require intensive supportive pulmonary care.

Acute eczematous contact dermatitis due to contact with liquid Stoddard solvent can be treated with traditional measures. Monitor for secondary infection, and treat with topical or systemic antibiotics as needed.


Chronic Exposure

Whether systemic health effects occur from low-level, chronic exposures to Stoddard solvent is uncertain. If symptoms persist, investigate other sources of exposure to Stoddard solvent or similar agents, and other etiologies. In cases of persistent neurologic symptoms, formal neuropsychologic testing may be useful for diagnostic purposes and to establish baseline functioning.


Challenge

6.How will you treat the patient and manage the case?

Previous Section

Next Section

Revised 2000-10-18.